Aligos Q3 net loss $31.5M; Phase 2 HBV study enrolling; cash $99.1M

Aligos Therapeutics, Inc.

2025-Q3 EPS reported -$0.44 revenue$2,017,000

Net loss of $31.5M in Q3 2025 vs $19.3M in Q3 2024; diluted EPS loss of $3.04.
Cash, cash equivalents and investments $99.1M as of Sep 30, 2025; runway into Q3 2026.
Phase 2 B-SUPREME trial of pevifoscorvir sodium (CAM-E) for chronic HBV enrolled first patient Aug 2025; interim data 2026.
Preclinical combo data with ALG-055009 (THR-β) and incretin RAs showed synergistic weight loss; out-licensing discussions ongoing.
R&D expenses rose to $23.9M (from $16.8M) driven by Phase 2 costs; G&A $5.2M (from $4.6M) due to legal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.